Huang Y , Bharill S , Karandur D , Peterson SM , Marita M , Shi X , Kaliszewski MJ , Smith AW , Isacoff EY , Kuriyan J .

R01 GM117051 NIGMS NIH HHS , R15 EY024451 NEI NIH HHS , R01 CA096504 NCI NIH HHS

	Figure 1. Schematic diagrams of EGFR structure.(A) The canonical model for the monomer to dimer transition in EGFR that is triggered by ligand binding (Kovacs et al., 2015a; Lemmon et al., 2014). (B) Domain boundaries in human EGFR. The residue numbers do not include the 24 residue signal sequence.DOI: http://dx.doi.org/10.7554/eLife.14107.002
	Figure 2. Monitoring the stoichiometry of human EGFR in Xenopus oocytes by photobleaching.(A) Schematic diagram illustrating the analysis of transiently-transfected EGFR by TIRF microscopy. A single oocyte is placed on a glass coverslip for observation and evanescent wave excitation is elicited by total internal reflection of the laser beam. The bright spots represent fluorescence from the EGFP fused to the C-terminus of EGFR. (B) Representative photobleaching traces of individual spots for EGFR without EGF. Image above shows a single image from a movie of the field of view. The two graphs show examples of one-step (left) and two-step (right) photobleaching. Frames collected at 20 Hz over 25 s.DOI: http://dx.doi.org/10.7554/eLife.14107.003
	Figure 3. Analysis of photobleaching events for EGFR without EGF, in the Xenopus assay.(A) Histogram of one-step and two-step photobleaching events for wild-type EGFR in the absence of EGF. This histogram represents the number of counted events. For subsequent analysis, the fraction of two-step events (3%) seen for a monomer control protein (Claudin-16) in a similar experiment at a comparable density was subtracted from the fraction of two-step events seen for EGFR and EGFR variants. The fraction of two-step photobleaching events for wild-type EGFR (WT) is compared to that for mutants. (B) Δ-arm, deletion of the dimerization arm, residues 242 to 259. (C) Δ-tether, mutation in Domain IV that breaks the autoinhibitory interaction, (D563A, H566A and deletion of residues 575 to 585).DOI: http://dx.doi.org/10.7554/eLife.14107.004
	Figure 4. Analysis of photobleaching events for EGFR in the presence of EGF.(A) TIRF image of a Xenopus oocyte expressing EGFR, 2 mins after addition of 15 nM EGF. Five representative photobleaching traces are shown, in which two to six photobleaching events can be identified. Traces with more than two steps are denoted 'multistep'. (B) Histogram showing the fraction of one-step, two-step and multistep photobleaching events for wild-type EGFR in the presence of 15 nM EGF. (C) As in B, for a kinase-dead mutant of EGFR (D813N). (D) As in B, for TGF-α as the ligand, at a concentration of 15 nM. (E) As in B, but for a 133-fold higher concentration of EGF (2 μM).DOI: http://dx.doi.org/10.7554/eLife.14107.005
	Figure 5. Effects on multimerization of mutations in EGFR that also affect dimerization.(A) Schematic diagram showing the locations of mutations with respect to the EGFR dimer. Δ-arm, deletion of the dimerization arm of the extracellular module. TM, mutations in the transmembrane helix (Thr 624, Gly 625, Gly 628, Gly 629, Ala 637 and Gly 641 are all replaced by isoleucine). Asymmetric dimer interface mutations combine the mutations I682Q in the N-lobe and V924R in the C-lobe of the kinase domain. (B) Histogram showing the fraction of one-step, two-step and multistep photobleaching events in Xenopus oocytes for wild-type and mutant EGFRs.DOI: http://dx.doi.org/10.7554/eLife.14107.006Figure 5—figure supplement 1. Dimerization of the isolated transmembrane helix.The EGFR transmembrane helix was fused to mCherry at the N-terminus and to EGFP at the C-terminus. The fraction of one-step and two-step photobleaching events of EGFP in Xenopus oocytes is shown for this construct. No multistep photobleaching events were observed.DOI: http://dx.doi.org/10.7554/eLife.14107.007
	Figure 6. Identification of a possible interface between the Domain IV legs of two EGFR molecules.(A) A representative dimer generated by ClusPro from a docking calculation done using a single isolated Domain IV. The interface between the two domains is not involved in dimerization, and is on the opposite face of the domain with respect to the interface involved in autoinhibitory tethering. (B) Residues on Domain IV that were mutated to examine their effects on multimerization and activity. (C) Histogram of the fractions of one-step, two-step and multistep photobleaching events in Xenopus oocytes for wild-type and mutant EGFR. IIIV/AARE: I545A, I556A, I562R and V592E. IIIV/KKRE: I545K, I556K, I562R and V592E. VEN/ERR: V526E, E527R and N528R. TN/RR: T548R and N554R.DOI: http://dx.doi.org/10.7554/eLife.14107.008
	Figure 7. Pulsed-interleaved excitation fluorescence cross-correlation spectroscopy (PIE-FCCS) data for EGFR expressed in COS-7 cells.For each protein, EGFP and mCherry fusions are coexpressed via transient transfection, and the cross-correlation between them is calculated for individual cells and reported as a fraction correlated, fc, indicated in the scatter plot. The red line represents the median value of the distribution, with the box enclosing the 25–75 percentile and the whiskers the entire distribution. Outliers are indicated by a red cross. (A) Data for control constructs, shown schematically at the top of the panel. These constructs are localized to the membrane by a thirteen residue N-terminal sequence from c-Src, and have either EGFP or mCherry fused to the C-terminus, as described (Endres et al., 2013). A multimer control, Src13-GCN4-EGFRk, is a construct with the coiled-coil segment of GCN4 joined to the N-terminus of the kinase domain of EGFR. The dimer control, Src13-GCN4, contains just the coiled-coil segment of GCN4 in addition to the membrane tag and the fluorescent protein. The monomer control, Src16, contains only the membrane localization sequence and the flurescent protein. Note that the cross-correlation values for multimeric Src13-GCN4-EGFRk are higher than that for the dimer control, as previously reported (Marita et al., 2015). (PIE-FCCS data for these controls were collected previously on the same instrument, and are reproduced here with permission.) (B) Relative cross-correlation values for full-length EGFR constructs, with and without the addition of EGF: EGFR, wild-type EGFR; and EGFR-IIIV/KKRE, an EGFR quadruple mutant (I545K, I556K, I562R and V592E). (C) Protein mobility from PIE-FCCS data. The mobility of each construct in the plasma membrane is directly measured with PIE-FCCS and converted to an effective diffusion coefficient for comparison. The diffusion coefficients of EGFR and EGFR-IIIV/KKRE before ligand stimulation are 0.46 ± 0.02 and 0.52 ± 0.02 μm2/s respectively ( ± standard error). These values are consistent with monomeric, single pass transmembrane proteins in the plasma membrane (Marita et al., 2015). Upon stimulation with EGF, the diffusion coefficient of EGFR-IIIV/KKRE drops to 0.40 ± 0.01 μm2/s, consistent with a monomer-dimer transition. For wild-type EGFR, EGF stimulation causes the diffusion coefficient to be reduced significantly more than for the mutant, to 0.28 ± 0.01 μm2/s, consistent with the formation of multimers.DOI: http://dx.doi.org/10.7554/eLife.14107.009Figure 7—figure supplement 1. Distributions of fc values for EGFR (+EGF), EGFR-IIIV/KKRE (+EGF) and the two positive controls, Src13-GCN4-EGFRk and Src13-GCN4.The fc data from Figure 7A and B is binned at increments of 0.025, normalized, and displayed to compare both receptors to both of the positive controls. Each pairwise comparison is statistically significant (p<0.001, by two-sample Student’s t-test), with the p-values displayed in each plot. For EGFR (+EGF) the distribution of fc lines up much more closely with the multimer control than the dimer control. For EGFR-IIIV/KKRE (+EGF) the fc distribution compares more favorably with the dimer control.DOI: http://dx.doi.org/10.7554/eLife.14107.010
	Figure 8. Effect of Domain IV mutations on phosphorylation of EGFR and two effector proteins.Wild-type (WT) or mutant EGFR was transfected into HEK293T cells, and phosphorylation was measured using FACS. The EGFR mutants are: II/KK (I545K, I556K); VEN/ERR (V526E, E527R and N528R); TN/RR (T548R and N554R). (A) Phosphorylation of a proximal site (Tyr 992) in EGFR. The bar graph shows the average phosphorylation level from cells expressing an intermediate level of EGFR, selected based on the whole range of EGFR expression in the FACS analysis, with (orange) and without (blue) the addition of EGF. (B) As in Panel A, for a distal site (Tyr 1173) in EGFR. (C) As in Panels A and B, for phosphorylation of PI3K. In addition to two mutations in Domain IV (II/KK and VEN/ERR), the phosphorylation levels for a kinase-dead EGFR variant (D813N) are shown. (D) Phosphorylation of ERK. The levels of phosphorylated ERK (pERK) show a bimodal distribution, with cells tending to have either low or high levels of pERK. The data are best represented as a histogram of cell numbers with different levels of pERK, as described (Kovacs et al., 2015b). Note that the response of two Domain IV mutants (II/KK and VEN/ERR) resembles that of the wild-type EGFR. For comparison, data for kinase-dead EGFR (D813N) show a reduced population of cells with high levels of pERK.DOI: http://dx.doi.org/10.7554/eLife.14107.011Figure 8—figure supplement 1. Transmembrane helix mutations.Effect on PI3K and ERK phosphorylation of mutation in the transmembrane helix (Thr 624, Gly 625, Gly 628, Gly 629, Ala 637 and Gly 641 are all replaced by isoleucine; compare with Figure 5). Data for PI3K and for ERK are shown as in Figure 8.DOI: http://dx.doi.org/10.7554/eLife.14107.012
	Figure 8—figure supplement 2. Surface expression of wild-type EGFR and II/KK mutant.(A) Total receptor (cyan) show some intracellular stores of receptor but very efficient trafficking of wild-type and II/KK (I545K/I556K) EGFR to the cell surface (magenta). (B) Quantification of surface/total ratio of approximately 100 cells from three independent experiments (error bars are SEM from N=3). The ratio is calculated from integrated fluorescence intensity values from each channels. (C) Representative data from one independent experiment show plot of raw total versus surface values. Each point is a region of interest (ROI), which is roughly equivalent to one cell.DOI: http://dx.doi.org/10.7554/eLife.14107.013
	Figure 9. Proximal and distal tail phosphorylation of EGFR in co-transfections with activator-impaired and receiver-impaired mutants.In these experiments, activator-impaired EGFR (V924R; denoted VR; salmon subunit) is fused to EGFP at the C-terminus and receiver-impaired EGFR (I682Q; denoted IQ; yellow subunit) is fused to mCherry. Phosphorylation is measured after co-transfection of both constructs, with and without EGF. (A) Tyr 1173, located in the distal portion of the tail, is present in both tails (denoted 1), in only the tail of receiver-impaired EGFR (denoted 2) or in only the activator-impaired tail (denoted 3). The bar graphs show phosphorylation levels for Tyr 1173. (B) As in Panel A, for a site in the proximal part of the tail, Tyr 992. Note that addition of EGF leads to only a very small increase in phosphorylation of Tyr 992 when the kinase bearing that residue is receiver-impaired.DOI: http://dx.doi.org/10.7554/eLife.14107.014
	Figure 10. Lateral phosphorylation of the tail of EGFR.Top) Schematic of kinase-active EGFR (Enzyme-EGFR) that is co-transfected with a kinase-dead variant (D813N; Substrate-EGFR), as shown in the schematic diagram. Tyr 1173 in Enzyme-EGFR is replaced by alanine. Four variants of substrate-EGFR are used: (1) kinase-dead EGFR, with no other mutations, denoted DN, (2) kinase-dead EGFR that is also receiver-impaired, IQ/DN, (3) kinase-dead EGFR that is also activator-impaired, DN/VR, and (4) kinase-dead EGFR that is also activator- and receiver-impaired, IQ/DN/VR. Bottom) Bar graph showing phosphorylation levels for Tyr1173, with and without EGF. Note that Substrate-EGFR that is activator-impaired shows no increase in phosphorylation above the basal level upon EGF addition.DOI: http://dx.doi.org/10.7554/eLife.14107.015
	Figure 11. A model for EGFR multimerization.(A) Two orthogonal views of a tetramer of extracellular modules, selected manually from ClusPro solutions for docking dimers (PDB code: 3NJP) with the constraint that the residues in Domain IV that affect multimerization are located at the interface between dimers. (B) A model for an EGFR tetramer, generated by connecting the model shown in Panel A to the structure of the dimeric transmembrane helices (PDB code 2M20) and a chain of kinase domains (PDB codes: 2GS6 and 3GOP). A schematic representation of the tetramer is shown on the right. (C) Schematic diagram indicating how higher-order multimers might be generated by repeating the interactions used to generate the model for the tetramer.DOI: http://dx.doi.org/10.7554/eLife.14107.016Figure 11—figure supplement 1. Summary of EGFR variants studied in this work and their effects on EGFR activity and multimerization.EGFR autophosphorylation in Tyr 992 and Tyr 1173, and the phosphorylation of PI3K and ERK were monitored by FACS assay using mammalian cells. To analyze the EGFR stoichiometry, with or without EGF, stepwise photobleaching counting experiments were done in Xenopus oocytes and PIE-FCCS data was measured in mammalian cells.DOI: http://dx.doi.org/10.7554/eLife.14107.017
	Figure 11—figure supplement 2. The Domain IV interface in crystal structures of the extracellular dimers of EGFR (left; PDB code 3NJP) and HER4 (right; PDB code 3U7U).Two orthogonal views of each structure are shown. The C-terminal tips of the extracellular module are close together in EGFR, and further apart in HER4. When the extracellular module is aligned symmetrically with respect to the membrane plane, the configuration of Domain IV in EGFR has the Domain IV multimer interface nearly vertical to the membrane plane. This allows stacking interactions between dimers to be perpetuated while retaining connection to a planar membrane. If the tips are splayed apart, as in the HER4 structure, then stacking between dimers would generate a rotation away from the membrane. For this reason, we used the structure of EGFR to generate a model for the tetramer.DOI: http://dx.doi.org/10.7554/eLife.14107.018
	Figure 11—figure supplement 3. Coarse-grained molecular dynamics simulation in a lipid bilayer.The model shown in Figure 11B was converted to a coarse-grained representation (Marrink et al., 2007) and inserted in an lipid bilayer, as shown on the left. A 1 μs molecular dynamics trajectory was generated, and a representative structure towards the end of the trajectory is shown on the right. The Domain IV interface and the interfaces between kinase domains remain stable during the trajectory (see Figure 11—figure supplement 4).DOI: http://dx.doi.org/10.7554/eLife.14107.019
	Figure 11—figure supplement 4. Structural integrity of the tetramer model in coarse-grained molecular dynamics simulation.(A) The distance between two pairs of residues across the Domain IV simulation are shown over the length of the trajectory. (B) The distance between two residues that are across from each other at each of the three kinase dimer interfaces is shown over the length of the trajectory. For this analysis, the kinases are denoted A, B, C and D, as shown in the schematic diagram. A and B are linked by a juxtamembrane latch, as are C and D. No juxtamembrane latch was included between kinases B and C. The displacement between kinases C and D is larger, as a consequence, but all three interfaces are stable.DOI: http://dx.doi.org/10.7554/eLife.14107.020

Aertgeerts, Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. 2011, Pubmed

Aertgeerts, Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein. 2011, Pubmed
Alvarado, Structural basis for negative cooperativity in growth factor binding to an EGF receptor. 2010, Pubmed
Arkhipov, Architecture and membrane interactions of the EGF receptor. 2013, Pubmed
Arkhipov, Her2 activation mechanism reflects evolutionary preservation of asymmetric ectodomain dimers in the human EGFR family. 2013, Pubmed
Batzer, Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. 1994, Pubmed
Bussi, Canonical sampling through velocity rescaling. 2007, Pubmed
Case, The Amber biomolecular simulation programs. 2005, Pubmed
Chen, Subunit composition of a DEG/ENaC mechanosensory channel of Caenorhabditis elegans. 2015, Pubmed , Xenbase
Chung, Spatial control of EGF receptor activation by reversible dimerization on living cells. 2010, Pubmed
Citri, The deaf and the dumb: the biology of ErbB-2 and ErbB-3. 2003, Pubmed
Clayton, Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis. 2005, Pubmed
Clayton, Predominance of activated EGFR higher-order oligomers on the cell surface. 2008, Pubmed
Comar, Time-resolved fluorescence spectroscopy measures clustering and mobility of a G protein-coupled receptor opsin in live cell membranes. 2014, Pubmed
Dawson, Ligand-induced structural transitions in ErbB receptor extracellular domains. 2007, Pubmed
Dawson, Epidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interface. 2005, Pubmed
DeFrees, Basis set limit geometries for ammonia at the SCF and MP2 levels of theory. 1984, Pubmed
Digman, Fluorescence correlation spectroscopy and fluorescence cross-correlation spectroscopy. 2009, Pubmed
Endres, Conformational coupling across the plasma membrane in activation of the EGF receptor. 2013, Pubmed
Endres, Emerging concepts in the regulation of the EGF receptor and other receptor tyrosine kinases. 2014, Pubmed
Ferguson, EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. 2003, Pubmed
Fleishman, A putative molecular-activation switch in the transmembrane domain of erbB2. 2002, Pubmed
Garrett, Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. 2002, Pubmed
Gong, Biochemical and biophysical analyses of tight junction permeability made of claudin-16 and claudin-19 dimerization. 2015, Pubmed
Heinzmann, Detection of epidermal growth factor receptor by scanning electron microscopy. 1994, Pubmed
Jones, A quantitative protein interaction network for the ErbB receptors using protein microarrays. 2006, Pubmed
Jones, Binding specificities and affinities of egf domains for ErbB receptors. 1999, Pubmed
Jura, Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. 2009, Pubmed
Jura, Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. 2011, Pubmed
Jura, Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. 2009, Pubmed
Koland, Coarse-grained molecular simulation of epidermal growth factor receptor protein tyrosine kinase multi-site self-phosphorylation. 2014, Pubmed
Korennykh, The unfolded protein response signals through high-order assembly of Ire1. 2009, Pubmed
Kovacs, Analysis of the Role of the C-Terminal Tail in the Regulation of the Epidermal Growth Factor Receptor. 2015, Pubmed
Kovacs, A structural perspective on the regulation of the epidermal growth factor receptor. 2015, Pubmed
Kozakov, How good is automated protein docking? 2013, Pubmed
Kozer, Recruitment of the adaptor protein Grb2 to EGFR tetramers. 2014, Pubmed
Kozer, Exploring higher-order EGFR oligomerisation and phosphorylation--a combined experimental and theoretical approach. 2013, Pubmed
Leahy, Structure and function of the epidermal growth factor (EGF/ErbB) family of receptors. 2004, Pubmed
Lemmon, The EGFR family: not so prototypical receptor tyrosine kinases. 2014, Pubmed
Lemmon, Two EGF molecules contribute additively to stabilization of the EGFR dimer. 1997, Pubmed
Liu, A single ligand is sufficient to activate EGFR dimers. 2012, Pubmed
Lu, Structural evidence for loose linkage between ligand binding and kinase activation in the epidermal growth factor receptor. 2010, Pubmed
Lynch, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. 2004, Pubmed
Margolis, All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor. 1989, Pubmed
Marita, Class A Plexins Are Organized as Preformed Inactive Dimers on the Cell Surface. 2015, Pubmed
Marrink, The MARTINI force field: coarse grained model for biomolecular simulations. 2007, Pubmed
Mendrola, The single transmembrane domains of ErbB receptors self-associate in cell membranes. 2002, Pubmed
Mineev, Spatial structure of the transmembrane domain heterodimer of ErbB1 and ErbB2 receptor tyrosine kinases. 2010, Pubmed
Monticelli, The MARTINI Coarse-Grained Force Field: Extension to Proteins. 2008, Pubmed
Muthuswamy, Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- and heterodimers. 1999, Pubmed
Müller, Pulsed interleaved excitation. 2005, Pubmed
Nagy, Distribution of resting and ligand-bound ErbB1 and ErbB2 receptor tyrosine kinases in living cells using number and brightness analysis. 2010, Pubmed
Ogiso, Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. 2002, Pubmed
Opresko, Functional reconstitutional of the human epidermal growth factor receptor system in Xenopus oocytes. 1990, Pubmed , Xenbase
Paez, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. 2004, Pubmed
Pao, EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. 2004, Pubmed
Pike, Negative co-operativity in the EGF receptor. 2012, Pubmed
Pronk, GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. 2013, Pubmed
Qiu, Mechanism of activation and inhibition of the HER4/ErbB4 kinase. 2008, Pubmed
Red Brewer, Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. 2013, Pubmed
Red Brewer, The juxtamembrane region of the EGF receptor functions as an activation domain. 2009, Pubmed
Ruan, Mechanistic Insights into R776H Mediated Activation of Epidermal Growth Factor Receptor Kinase. 2015, Pubmed
Schlessinger, Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. 2002, Pubmed
Shan, Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. 2012, Pubmed
Shi, ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. 2010, Pubmed
Slamon, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. 2001, Pubmed
Sliwkowski, Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. 1994, Pubmed
Smith, Detection of rhodopsin dimerization in situ by PIE-FCCS, a time-resolved fluorescence spectroscopy. 2015, Pubmed
Sonnleitner, Structural rearrangements in single ion channels detected optically in living cells. 2002, Pubmed , Xenbase
Stamos, Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. 2002, Pubmed
Ulbrich, Subunit counting in membrane-bound proteins. 2007, Pubmed , Xenbase
Valley, Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer. 2015, Pubmed
Wassenaar, Computational Lipidomics with insane: A Versatile Tool for Generating Custom Membranes for Molecular Simulations. 2015, Pubmed
Yang, Optimized codon usage and chromophore mutations provide enhanced sensitivity with the green fluorescent protein. 1996, Pubmed
Yarden, Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. 1987, Pubmed
Yarden, Untangling the ErbB signalling network. 2001, Pubmed
Yarden, Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. 1987, Pubmed
Zhang, Quantification of epidermal growth factor receptor expression level and binding kinetics on cell surfaces by surface plasmon resonance imaging. 2015, Pubmed
Zhang, Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling. 2012, Pubmed
Zhang, An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. 2006, Pubmed
Zhen, Characterization of glycosylation sites of the epidermal growth factor receptor. 2003, Pubmed